Amlodipine/chlortalidone/losartan - Hanmi Pharmaceutical

Drug Profile

Amlodipine/chlortalidone/losartan - Hanmi Pharmaceutical

Alternative Names: HCP 1401

Latest Information Update: 07 Oct 2016

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antihypertensives; Small molecules
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 07 Oct 2016 Chemical structure information added
  • 01 Sep 2016 Hanmi Pharmaceutical completes a phase III trial in Hypertension in South Korea (unspecified route) (NCT02916602)
  • 01 Apr 2015 Phase-III clinical trials in Hypertension (Treatment-experienced) in South Korea (unspecified route) (NCT02916602)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top